Author

Serkan Yaman

Graduation Semester and Year

2019

Language

English

Document Type

Dissertation

Degree Name

Doctor of Philosophy in Biomedical Engineering

Department

Bioengineering

First Advisor

Kytai T. Nguyen

Second Advisor

Jon A. Weidanz

Abstract

Cell membrane-derived nanoparticles recently caught attention due to their desirable features in drug delivery such as mimicking properties of native tissue and cells, avoiding systemic clearance, and alleviating foreign body responses. Besides nanoparticle technology, adoptive immunotherapy has emerged for its promising treatment modalities, including cancer specificity. Our long-term goal for this research is to develop a biomimetic drug carrier based on chimeric antigen receptor (CAR) transduced T cell membranes. In the study, anti-cancer drug afatinib loaded poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) co-extruded with anti her-2 based chimeric antigen receptor (CAR) Jurkat T cell membranes. Anti her-2 CAR-T cells were produced by lentiviral transduction of anti her-2 chimeric antigenic receptor coding lentiviral plasmids. Anti her-2 CAR-T cells were characterized by their specific activities against her-2 antigen and used for cell membrane extraction. Anti her-2 CAR-T cell membrane coated PLGA nanoparticles (CAR-T-MNPs) characterized via fluorescent microscopy and flow cytometry. Membrane coated NPs showed ustained drug release over the course of 21 days and were stable up to 5 days. Afatinib loaded CAR-T-MNPs inhibited growth of A549 lung cancer cells in vitro. In addition, in vitro uptake studies revealed that CAR-T-MNPs showed an increased uptake by A549 cells. This results also confirmed via in vivo biodistribution studies using subcutaneous lung cancer model in nude mice that, of all studied groups, CAR-T-MNPs localized more at tumor areas compared to those of other studied groups. Therefore, new CAR modified cell membrane coated NP drug-delivery platform has shown its efficacy in vitro and in vivo. Proposed CAR based NPs are promising biomimetic delivery with its long circulation time and tumor site accumulation while opening a new way to personalized medicine and tumor specific targeting by patient's own cell membrane coated NP delivery.

Keywords

Nanoparticles, CAR-T cells, membrane-based drug delivery, cancer chemotherapy

Disciplines

Biomedical Engineering and Bioengineering | Engineering

Comments

Degree granted by The University of Texas at Arlington

30267-2.zip (4425 kB)

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.